Twin Peaks Wealth Advisors LLC Buys Shares of 704 Eli Lilly and Company (NYSE:LLY)

Twin Peaks Wealth Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 704 shares of the company’s stock, valued at approximately $410,000.

Several other large investors have also recently bought and sold shares of LLY. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the third quarter worth approximately $27,000. Retirement Group LLC lifted its stake in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC acquired a new position in shares of Eli Lilly and Company in the second quarter worth approximately $33,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $35,000. Finally, Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $36,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total value of $21,821,453.78. Following the sale, the insider now owns 99,719,884 shares of the company’s stock, valued at approximately $63,004,019,910.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 195,055 shares of company stock valued at $125,254,657 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. BMO Capital Markets upped their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $775.19 on Wednesday. The stock’s 50-day simple moving average is $725.15 and its 200 day simple moving average is $634.68. The stock has a market capitalization of $736.55 billion, a price-to-earnings ratio of 133.65, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 52-week low of $323.26 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.09 EPS. Research analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.